Cognitive scientists are helping artificial intelligence think more like us.
Currently in the United States, a prostate cancer drug is being touted in a novel way: The claimed primary benefit of the drug is not that it reduces the risk of the disease, but rather
APS Fellow Gerd Gigerenzer is the Director at the Center for Adaptive Behavior and Cognition at the Max Planck Institute for Human Development, Germany, where he investigates how humans and other animals make decisions and